Question explored with the scientific record
Conversation so far
- 1 Is ACI-24.060 a promising drug for Alzheimer’s
- 2 What phase is ACI-24.060 in, and when are results expected?
- 3 Is ACI-24.060 registered on ClinicalTrials.gov or EU CTR?
Answered on this page ↓
Is ACI-24.060 registered on ClinicalTrials.gov or EU CTR?
The short version: I can't confirm ACI-24.060 is registered on either registry. Nothing in front of me shows a ClinicalTrials.gov or EU CTR entry for it.
The closest record is a 2014 review of Alzheimer's vaccine candidates. It lists AC Immune's ACI-24 as a Phase I/II trial, with the vaccine built on an amyloid-beta fragment carried on a liposome membrane [1]. That is the earlier ACI-24, not the .060 version. No record here gives a registry identifier, a registration date, or a registry name for either compound.
Registration is a checkable fact, not a matter of evidence quality. You verify it by searching ClinicalTrials.gov and the EU CTR directly for "ACI-24.060" and for the sponsor, AC Immune. A trial can run without appearing in either place, and a listing can exist that this retrieval simply never touched. What I have cannot settle it either way.
My call: unconfirmed, not denied. Search both registries yourself before assuming either answer. Confidence: high that these records don't show a registration; not clear on whether one exists.
Sources used 1
-
Immunogenicity of DNA- and recombinant protein-based Alzheimer Disease epitope vaccines
This study investigates the immunogenicity of DNA and recombinant protein-based vaccines targeting Alzheimer’s disease epitopes, highlighting their potential to induce protective immune responses without harmful autoreactive T cell activation.
DOI: 10.4161/hv.27882